Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 8/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.57 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.36 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6505697 | 1.00 | OPRL1 (0.58) | OPRL1KCNH2OPRM1MCHR1AVPR1A | |
| SCHEMBL6506703 | 0.91 | OPRL1 (0.47) | OPRL1KCNH2OPRM1MCHR1 | |
| SCHEMBL6506699 | 0.91 | OPRL1 (0.47) | OPRL1KCNH2OPRM1MCHR1 | |
| SCHEMBL6502926 | 0.88 | OPRL1 (0.70) | OPRL1KCNH2OPRM1AVPR1ASIGMAR1 | |
| SCHEMBL6502587 | 0.85 | OPRL1 (0.58) | OPRL1KCNH2OPRM1MCHR1SIGMAR1 | |
| SCHEMBL6502586 | 0.85 | OPRL1 (0.58) | OPRL1KCNH2OPRM1MCHR1SIGMAR1 | |
| SCHEMBL6501020 | 0.80 | OPRL1 (0.59) | OPRL1KCNH2OPRM1SIGMAR1 | |
| SCHEMBL6501015 | 0.80 | OPRL1 (0.59) | OPRL1KCNH2OPRM1SIGMAR1 | |
| SCHEMBL6472714 | 0.78 | OPRL1 (0.57) | OPRL1KCNH2OPRM1 | |
| SCHEMBL6471078 | 0.73 | OPRL1 (1.00) | OPRL1KCNH2OPRM1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050153998-A1 | Tetrahydroisoquinoline or isochroman compounds | ITO FUMITAKA (JP) | 2005-07-14 | — | — | US | disclosed |
| US-20050043313-A1 | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153998-A1 | Tetrahydroisoquinoline or isochroman compounds | OPRL1, NR1H3, HRH3 | OPRL1 1/4885KCNH2 378/4885OPRM1 8/4885 |
| US-20050043313-A1 | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade | TFPI, TFPI2, PLAT | OPRL1 4418/4885KCNH2 1662/4885OPRM1 4656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.